Literature DB >> 22435382

Eculizumab in a patient with dense-deposit disease.

Erica Daina, Marina Noris, Giuseppe Remuzzi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22435382     DOI： 10.1056/NEJMc1112273

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  61 in total

1.  Glomerular disease: Eculizumab for the treatment of MPGN.

Authors:  Susan J Allison
Journal:  Nat Rev Nephrol       Date:  2012-04-10       Impact factor: 28.314

2.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

3.  American Society of Nephrology clinical pathological conference.

Authors:  Kevin E Meyers; Helen Liapis; Mohamed G Atta
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

4.  Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.

Authors:  Serena Bettoni; Elena Bresin; Giuseppe Remuzzi; Marina Noris; Roberta Donadelli
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

5.  C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Authors:  Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

6.  Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.

Authors:  Marieta M Ruseva; Tao Peng; Melissa A Lasaro; Keith Bouchard; Susan Liu-Chen; Fang Sun; Zhao-Xue Yu; Andre Marozsan; Yi Wang; Matthew C Pickering
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

Review 7.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

8.  Rituximab fails where eculizumab restores renal function in C3nef-related DDD.

Authors:  Caroline Rousset-Rouvière; Mathilde Cailliez; Florentine Garaix; Daniele Bruno; Daniel Laurent; Michel Tsimaratos
Journal:  Pediatr Nephrol       Date:  2014-01-10       Impact factor: 3.714

Review 9.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

10.  Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Authors:  Ozan Ozkaya; Hulya Nalcacioglu; Demet Tekcan; Gurkan Genc; Bilge Can Meydan; B Handan Ozdemir; M Kemal Baysal; Hasan Tahsin Keceligil
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.